XML 110 R22.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2019
Share-based Payment Arrangement [Abstract] |
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATION The 2006 Employee Plan authorizes the Board of Directors, or a committee of the Board of Directors, to issue or transfer up to an aggregate of 23,700,000 shares of common stock, plus any shares relating to awards that expire, are forfeited or canceled. The Company issues new shares upon exercise of option rights and vesting of restricted stock units (RSUs). The Employee Plan permits the granting of option rights, appreciation rights, restricted stock, RSUs, performance shares and performance units to eligible employees. At December 31, 2019, no appreciation rights, performance shares or performance units had been granted under the 2006 Employee Plan. The 2006 Stock Plan for Nonemployee Directors (Nonemployee Director Plan) authorizes the Board of Directors, or a committee of the Board of Directors, to issue or transfer up to an aggregate of 200,000 shares of common stock, plus any shares relating to awards that expire, are forfeited or canceled. The Nonemployee Director Plan permits the granting of option rights, appreciation rights, restricted stock and RSUs to members of the Board of Directors who are not employees of the Company. At December 31, 2019, no option rights or appreciation rights had been granted under the Nonemployee Director Plan. In connection with the acquisition of Valspar (see Note 3), the Company assumed certain outstanding RSUs of Valspar granted under the Amended and Restated 2015 Omnibus Equity Plan. Upon close of the acquisition, the Valspar RSUs were converted into RSUs relating to common stock of the Company. The cost of the Company’s stock-based compensation is recorded in accordance with the Stock Compensation Topic of the ASC. At December 31, 2019, the Company had total unrecognized stock-based compensation expense of $143.1 million that is expected to be recognized over a weighted-average period of 1.06 years. Stock-based compensation expense during 2019, 2018 and 2017 was $101.7 million, $82.6 million and $90.3 million, respectively. The related tax benefit was $25.1 million, $20.5 million and $34.3 million during 2019, 2018 and 2017, respectively. Excess tax benefits from share-based payments are recognized as an income tax benefit in the statement of consolidated income when options are exercised and RSUs vest. For the years ended December 31, 2019, 2018 and 2017, the Company's excess tax benefit from options exercised and RSUs vested reduced the income tax provision by $65.2 million, $43.4 million, and $86.5 million respectively. Option Rights The fair value of the Company’s option rights was estimated at the date of grant using a Black-Scholes-Merton option-pricing model with the following weighted-average assumptions for all options granted:
| 2019 |  | 2018 |  | 2017
Risk-free interest rate | 1.64 | % |  | 2.99 | % |  | 1.97 | %
Expected life of option rights | 5.05 years |  |  | 5.05 years |  |  | 5.05 years |
Expected dividend yield of stock | .87 | % |  | .89 | % |  | 0.85 | %
Expected volatility of stock | .232 |  |  | .211 |  |  | .213 |
The risk-free interest rate is based upon the U.S. Treasury yield curve at the time of grant. The expected life of option rights was calculated using a scenario analysis model. Historical data was used to aggregate the holding period from actual exercises, post-vesting cancellations and hypothetical assumed exercises on all outstanding option rights. The expected dividend yield of stock is the Company’s best estimate of the expected future dividend yield. Expected volatility of stock was calculated using historical and implied volatilities. Grants of option rights for non-qualified and incentive stock options have been awarded to certain officers and key employees under the 2006 Employee Plan. The option rights generally become exercisable to the extent of one-third of the optioned shares for each full year following the date of grant and generally expire ten years after the date of grant. Unrecognized compensation expense with respect to option rights granted to eligible employees amounted to $67.8 million at December 31, 2019. The unrecognized compensation expense is being amortized on a straight-line basis over the three-year vesting period, net of estimated forfeitures based on historical activity, and is expected to be recognized over a weighted-average period of 1.10 years. The weighted-average per share grant date fair value of options granted during 2019, 2018 and 2017 was $116.41, $90.86 and $77.14, respectively. The total intrinsic value of option rights exercised during 2019, 2018, and 2017 was $285.8 million, $190.2 million and $255.5 million, respectively. The total fair value of options vested during 2019, 2018 and 2017 was $43.2 million, $38.6 million and $31.3 million, respectively. There were no outstanding option rights for nonemployee directors at December 31, 2019, 2018 and 2017. A summary of the Company’s non-qualified and incentive stock option right activity is shown in the following table:
| 2019 |  | 2018 |  | 2017
| Optioned Shares |  | Weighted- Average Exercise Price Per Share |  | Aggregate Intrinsic Value (in millions) |  | Optioned Shares |  | Weighted- Average Exercise Price Per Share |  | Aggregate Intrinsic Value (in millions) |  | Optioned Shares |  | Weighted- Average Exercise Price Per Share |  | Aggregate Intrinsic Value (in millions)
Outstanding at beginning of year | 4,485,249 |  |  | $ | 238.53 |  |  |  |  | 4,646,313 |  |  | $ | 204.33 |  |  |  |  | 5,163,709 |  |  | $ | 163.61 |  |  |
Granted | 498,886 |  |  | 549.32 |  |  |  |  | 565,336 |  |  | 410.00 |  |  |  |  | 689,506 |  |  | 377.84 |  |  |
Exercised | (902,166 | ) |  | 171.37 |  |  |  |  | (662,218 | ) |  | 137.03 |  |  |  |  | (1,154,698 | ) |  | 123.16 |  |  |
Forfeited | (40,312 | ) |  | 380.13 |  |  |  |  | (60,288 | ) |  | 327.08 |  |  |  |  | (49,977 | ) |  | 267.02 |  |  |
Expired | (1,928 | ) |  | 345.68 |  |  |  |  | (3,894 | ) |  | 238.26 |  |  |  |  | (2,227 | ) |  | 236.97 |  |  |
Outstanding at end of year | 4,039,729 |  |  | $ | 290.45 |  |  | $ | 1,184.0 |  |  | 4,485,249 |  |  | $ | 238.53 |  |  | $ | 704.2 |  |  | 4,646,313 |  |  | $ | 204.33 |  |  | $ | 955.8 |
Exercisable at end of year | 2,973,656 |  |  | $ | 226.51 |  |  | $ | 1,061.7 |  |  | 3,274,780 |  |  | $ | 188.48 |  |  | $ | 671.3 |  |  | 3,288,237 |  |  | $ | 156.43 |  |  | $ | 833.9 |
The weighted-average remaining term for options outstanding at the end of 2019, 2018 and 2017 was 6.02, 6.09 and 6.28 years, respectively. The weighted-average remaining term for options exercisable at the end of 2019, 2018 and 2017 was 4.95, 5.01 and 5.11 years, respectively. Shares reserved for future grants of option rights, restricted stock and RSUs were 4,217,446, 5,135,822 and 6,041,092 at December 31, 2019, 2018 and 2017, respectively. RSUs Grants of RSUs, which generally require three years of continuous employment from the date of grant before vesting and receiving the stock without restriction, have been awarded to certain officers and key employees under the 2006 Employee Plan. The February 2019, 2018 and 2017 grants consisted of performance-based awards that vest at the end of a three-year period based on the Company’s achievement of specified financial and operating performance goals relating to earnings per share and return on net assets employed. Unrecognized compensation expense with respect to grants of RSUs to eligible employees amounted to $73.6 million at December 31, 2019 and is being amortized on a straight-line basis over the vesting period and is expected to be recognized over a weighted-average period of 0.93 years. Grants of RSUs have been awarded to nonemployee directors under the Nonemployee Director Plan. These grants generally vest and stock is received without restriction to the extent of one-third of the RSUs for each year following the date of grant. Unrecognized compensation expense with respect to grants of RSUs to nonemployee directors amounted to $1.7 million at December 31, 2019 and is being amortized on a straight-line basis over the three-year vesting period and is expected to be recognized over a weighted-average period of 0.96 years. A summary of the Company’s RSU activity for the years ended December 31 is shown in the following table:
| 2019 |  | 2018 |  | 2017
Outstanding at beginning of year | 290,402 |  |  | 335,796 |  |  | 397,326 |
Granted | 131,275 |  |  | 116,636 |  |  | 112,647 |
Exchanged Valspar awards (net of forfeitures) |  |  |  |  |  |  | 51,009 |
Vested | (168,730 | ) |  | (150,576 | ) |  | (215,433 | )
Forfeited | (4,775 | ) |  | (11,454 | ) |  | (9,753 | )
Outstanding at end of year | 248,172 |  |  | 290,402 |  |  | 335,796 |
The weighted-average per share fair value of RSUs granted during 2019, 2018 and 2017 was $432.55, $404.08 and $313.88, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration